Market
Next EU regulatory action for Dato-DXd by end of 2025?
2
Resolution / Starting Odds
Reapplication for approval • 25%
Approval in a different indication • 25%
Complete withdrawal from EU market • 25%
No action • 25%
European Medicines Agency announcements or AstraZeneca/Daiichi Sankyo press releases
Story
AstraZeneca and Daiichi Sankyo Withdraw EU Application for Lung Cancer Drug Datopotamab Deruxtecan Due to Non-Significant Survival Improvement
Dec 24, 2024, 11:37 AM
AstraZeneca, in collaboration with Daiichi Sankyo, has voluntarily withdrawn its marketing authorization application for the lung cancer drug datopotamab deruxtecan ($Dato-DXd) from the European Union's medicines regulator. The decision follows feedback from the European Medicines Agency after trial results from the phase advanced study TROPION-Lung01 showed that the drug did not significantly improve patient survival rates. The drug, also known as Dato-DXd, had previously received the designation of innovative therapy from the U.S. Food and Drug Administration earlier this month for its results in treating a specific type of lung cancer. Dato-DXd belongs to a promising group of treatments known as antibody-drug conjugates.
View original story
Similar markets
European Union • 25%
China • 25%
Other • 25%
Japan • 25%
Further Investigation • 25%
Fines • 25%
Operational Restrictions • 25%
No Further Action • 25%
Approved • 33%
Request for more data • 34%
Rejected • 33%
No significant milestone • 25%
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
BaFin (Germany) • 25%
European Central Bank • 25%
US SEC • 25%
Other • 25%